Benzinga | Nov 5, 2021 09:33AM EDT

Nektar Therapeutics Q3 EPS $(0.70) Beats $(0.80) Estimate, Sales $24.92M Miss $27.87M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.80) by 12.5 percent. This is a 14.75 percent decrease over losses of $(0.61) per share from the same period last year. The company reported quarterly sales of $24.92 million which missed the analyst consensus estimate of $27.87 million by 10.58 percent. This is a 17.02 percent decrease over sales of $30.03 million the same period last year.